Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2

Area of Science:

• Molecular Biology
• Infectious Diseases
• Biotechnology

Background:

• The COVID-19 pandemic underscored the need for advanced diagnostic technologies to control disease spread.
• Current diagnostic methods can be time-consuming and require specialized laboratory infrastructure.

Purpose of the Study:

• To develop a sensitive, specific, and rapid diagnostic tool for SARS-CoV-2 RNA detection.
• To simplify assay preparation and reduce turnaround time for infectious disease diagnostics.

Main Methods:

• Development of SHINE (Streamlined Highlighting of Infections to Navigate Epidemics) using RPA-based amplification and Cas13-based detection in a single step.
• Improvement of the HUDSON protocol for rapid virus inactivation from patient samples (nasopharyngeal swabs, saliva) within 10 minutes.
• Integration of an in-tube fluorescent readout and a smartphone application for simplified result interpretation and reduced contamination risk.

Main Results:

• SHINE demonstrated 90% sensitivity and 100% specificity in validating against RT-qPCR using 50 nasopharyngeal patient samples.
• Achieved a sample-to-answer time of 50 minutes, significantly reducing diagnostic turnaround.
• The assay allows for detection of SARS-CoV-2 RNA from unextracted samples, simplifying the workflow.

Conclusions:

• SHINE is a highly sensitive and specific diagnostic tool for SARS-CoV-2 RNA detection.
• The assay's simplified workflow, rapid results, and potential for point-of-care use can enhance global diagnostic capabilities for infectious diseases.
• SHINE offers a promising solution for disease surveillance and management outside traditional laboratory settings.